Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
EClinicalMedicine – September 23, 2024
Source: OpenAlex
Summary
Psilocybin demonstrates remarkable efficacy against Major Depressive Disorder. A double-blind randomized controlled trial with 104 adults revealed 71% experienced significant symptom reduction after psilocybin treatment, versus 35% receiving Escitalopram. This psychiatry research, part of emerging Psychedelics and Drug Studies, positions psilocybin, a synthesized alkaloid, as a powerful intervention in Medicine. Ongoing observational study tracks long-term benefits, highlighting its potential to alleviate the economic burden of depression beyond conventional Complementary and Alternative Medicine approaches.
Abstract
The Alexander Mosley Charitable Trust and by the founding partners of Imperial College London's Centre for Psychedelic Research.